Ertl B, Platzer P, Wirth M, Gabor F
Institute of Pharmaceutical Technology, the University of Vienna, Althanstrasse 14, A-1090, Vienna, Austria.
J Control Release. 1999 Sep 20;61(3):305-17. doi: 10.1016/s0168-3659(99)00122-4.
Camptothecin (CPT) and its water-insoluble derivatives are known as topoisomerase-I inhibitors exhibiting high antitumoral activity against a wide spectrum of human malignancies. Until now clinical application of CPT is restricted by insolubility and instability of the drug in its active lactone form resulting in less antitumor potency and poor bioavailability. For these reasons CPT-loaded-microspheres were prepared by the solvent evaporation method using the H-series of poly(D,L-lactide-co-glycolide) (H-PLGA), which contain more carboxylic acid end chains and hydrate faster than the non-H-series. At 1.2% CPT-payload the drug was molecular dispersed throughout the matrix whereas at higher CPT-payload the amount of crystalline CPT-islets increased with the CPT content. The release pattern of CPT was biphasic comprising a first burst effect delivering 20-35% of the payload and increasing with drug-loading. This phase was followed by sustained delivery of CPT releasing 40-75% of the payload within 160 h. In comparison to PLGA-microspheres, the CPT-release rate from H-PLGA was twofold higher and accelerated. The active CPT-lactone was maintained during preparation, storage and release due to hindered diffusion of acidic oligomers among other mechanisms. Thus stabilization and sustained release of CPT from PLGA-microspheres might reduce local toxicity combined with prolonged efficacy offering new perspectives in CPT chemotherapy.
喜树碱(CPT)及其水不溶性衍生物是已知的拓扑异构酶-I抑制剂,对多种人类恶性肿瘤具有高抗肿瘤活性。到目前为止,CPT的临床应用受到药物活性内酯形式的不溶性和不稳定性的限制,导致抗肿瘤效力较低和生物利用度差。由于这些原因,采用溶剂蒸发法,使用聚(D,L-丙交酯-共-乙交酯)的H系列(H-PLGA)制备了载CPT微球,H-PLGA含有更多的羧酸端链,并且比非H系列水合更快。在1.2%的CPT载药量下,药物分子分散于整个基质中,而在较高的CPT载药量下,结晶CPT胰岛的量随CPT含量增加。CPT的释放模式是双相的,包括第一个突释效应,释放20%-35%的载药量,并随载药量增加而增加。此阶段之后是CPT的持续释放,在160小时内释放40%-75%的载药量。与PLGA微球相比,CPT从H-PLGA的释放速率高出两倍且加快。由于酸性低聚物的扩散受阻等机制,活性CPT内酯在制备、储存和释放过程中得以保持。因此,CPT从PLGA微球中的稳定化和持续释放可能会降低局部毒性并延长疗效,为CPT化疗提供新的前景。